1 – 38 of 38
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer’s Disease Detection and Dementia Risk Reduction : The AD-RIDDLE Project
2024) In Journal of Prevention of Alzheimer's Disease(
- Contribution to journal › Article
- 2021
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
Brain injury markers in blood associate with generalised oedema on computed tomography after cardiac arrest
(
- Contribution to conference › Abstract
- 2020
-
Mark
Quantification of total apolipoprotein e and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
(
- Contribution to journal › Article
- 2019
-
Mark
Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis
(
- Contribution to journal › Letter
- 2017
-
Mark
Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment
(
- Contribution to journal › Article
- 2016
-
Mark
Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele
(
- Contribution to journal › Article
-
Mark
Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology
(
- Contribution to journal › Article
- 2015
-
Mark
Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease
(
- Contribution to journal › Article
- 2014
-
Mark
The amyloid-β degradation pattern in plasma: A possible tool for clinical trials in Alzheimer's disease
(
- Contribution to journal › Article
- 2013
-
Mark
Serum but not Cerebrospinal Fluid levels of Insulin-Like Growth Factor-I (IGF-I) and IGF-Binding Protein-3 (IGFBP-3) are Increased in Alzheimer ́s Disease
2013) Endokrindagarna, 2013(
- Contribution to conference › Poster
-
Mark
The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms
(
- Contribution to journal › Article
- 2012
-
Mark
The determination of aggregated tau in solution and its potential as a tool for the diagnosis of tauopathies
2012) 16th Congress of the European-Federation-of-Neurological-Societies (EFNS) In European Journal of Neurology 19(Suppl. 1). p.98-98(
- Contribution to journal › Published meeting abstract
-
Mark
Age and diagnostic performance of Alzheimer disease CSF biomarkers
(
- Contribution to journal › Article
- 2011
-
Mark
The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.
(
- Contribution to journal › Article
-
Mark
Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
(
- Contribution to journal › Article
- 2010
-
Mark
CSF biomarkers predict a more malignant outcome in Alzheimer disease.
(
- Contribution to journal › Article
-
Mark
Changes in cerebrospinal fluid insulin during non-neurological surgery
2010) 23rd Congress Meeting of European-College-of-Neuropsychopharmacology In European Neuropsychopharmacology 20. p.328-329(
- Contribution to journal › Published meeting abstract
-
Mark
An enzyme activity as a potential biomarker for Alzheimer's disease.
2010) Alzheimer's Association International Conference on Alzheimer's Disease 2010 In Alzheimer's & Dementia 6(4). p.497-498(
- Contribution to journal › Published meeting abstract
-
Mark
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Convergence of chromogranin and amyloid metabolism in the brain.
2010) Alzheimer's Association International Conference on Alzheimer's Disease 2010 In Alzheimer's & Dementia 6(4). p.511-511(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
The PPAR-alpha gene in Alzheimer's disease: Lack of replication of earlier association
(
- Contribution to journal › Article
-
Mark
Changes in cerebrospinal fluid insulin during non-neurological surgery
2009) 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes In Diabetologia 52(Suppl 1). p.677-677(
- Contribution to journal › Published meeting abstract
-
Mark
EVOLUTION OF A beta 42 AND A beta 40 LEVELS AND A beta 42/A beta 40 RATIO IN PLASMA DURING PROGRESSION OF ALZHEIMER'S DISEASE: A MULTICENTER ASSESSMENT
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis
(
- Contribution to journal › Article
- 2008
-
Mark
Non-neurological surgery results in a neurochemical stress response
(
- Contribution to journal › Letter
-
Mark
Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides
(
- Contribution to journal › Article
- 2007
-
Mark
Cerebrospinal fluid protein reactions during non-neurological surgery
(
- Contribution to journal › Article
- 2005
-
Mark
The transcobalamin 776C > G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease
(
- Contribution to journal › Letter
-
Mark
Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF
(
- Contribution to journal › Article
- 2003
-
Mark
Increased frequency of a new polymorphism in the cycle 2 (cdc2) gene in patients with Alzheimer's disease frontotemporal dementia
(
- Contribution to journal › Article